Latest Infection Control News

Holista Colltech has received a formal notice from ASIC seeking recovery of approximately $1.09 million in legal costs related to Federal Court proceedings. The company is currently reviewing its options amid ongoing regulatory scrutiny.

Genetic Signatures Limited unveiled a year of strategic transformation and robust financial growth at its 2025 AGM, highlighting leadership renewal and a sharpened commercial focus. The company’s FY25 revenue jumped 66%, driven by strong product demand and expanded market presence.

Holista Colltech reported improved cash flow management and robust growth in its dietary supplements division for 3QFY25, while navigating ongoing legal challenges with ProImmune.

Holista Colltech has raised $2.295 million through a share placement to two international investors, aiming to bolster its operations and balance sheet. The move highlights the company’s ongoing efforts to support growth across its health and wellness divisions.

Genetic Signatures reported a 63% revenue increase to $15.9 million in FY25, alongside a 28% reduction in underlying losses and a strategic shift in its automated diagnostics platform development.

Genetic Signatures Limited reported a 63% revenue surge to $15.9 million in FY25, driven by strong Australian sales and progress in EMEA, while navigating a $20.1 million net loss and a strategic pivot towards partnerships for automated diagnostics.

Holista Colltech has confirmed Leong Man Loong as its permanent CEO, cementing leadership stability during a pivotal recovery phase. His symbolic $1 salary underscores a commitment to long-term growth.

Holista Colltech has closed its ASIC penalty chapter with a $900K final payment, raised $1.53 million through convertible notes, and reported a 10.9% year-on-year sales increase driven by its Dietary Supplements division.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

Holista Colltech Limited reports a notable financial recovery in 4QFY24, underpinned by strong cash inflows and a rebound in its Food Ingredients division, alongside a leadership change aimed at steering future growth.

Next Science reported a 2.9% revenue increase to US$22.8 million in FY24, driven by an 85% surge in XPERIENCE™ sales, while achieving adjusted EBITDA and cashflow positivity in 4Q FY24 amid strategic cost restructuring.